Devices

Michael Hill explains how the system works when a patient's blood glucose drops.

In this Exclusive Interview transcript, Dr. Richard Bergenstal discusses the first approval of a hybrid closed-loop system and the future of diabetes treatment, including a possible cure for type 1 diabetes.

In this Exclusive Interview, Dr. Richard Bergenstal talks with Diabetes in Control Publisher Steve Freed about the technology in the artificial pancreas, the new Abbott Libre CGMS, and the possible diabetes cure.

Let’s start off with what is in the pipeline.

Woman, 53 years of age, type 1 diabetes, has been wearing an insulin pump for 18 years. Recently changed insulin pumps. Not only upgraded on a certain brand, but now has a totally different brand. We did not change settings when she started with her new pump. She called to let me know her glucose levels were higher since she has her new pump.

Barrier means more work including monitoring more often and making more adjustments.

Recently Beta Bionics, the makers of the iLet artificial pancreas, reached a significant milestone: raising $1 million through online public fundraising. It is no longer a question of if an artificial pancreas will exist, but of when it will become commercially available. With every major insulin pump company working in this area, along with many startups, patients will not just have one system, but several they can chose from.

How do consumers and HCPs feel about new technologies and their impact on our health system?

Guest Post by David Kliff, Diabetic Investor
The FDA approved Dexcom’s request for a non-adjunctive claim this week. It looks like a bad situation for conventional glucose monitors, and believe it or not is about to get worse. Here’s why.

System shows significant improvement in HbA1c compared to current best therapy available.